

## DEPARTMENT OF DEFENSE ARMED FORCES EPIDEMIOLOGICAL BOARD 5109 LEESBURG PIKE FALLS CHURCH, VA 22041-3258



AFEB (15-1a) 98-3

09 January 1998

MEMORANDUM FOR THE ASSISTANT SECRETARY OF DEFENSE (HEALTH AFFAIRS)

THE SURGEON GENERAL, DEPARTMENT OF THE ARMY
THE SURGEON GENERAL, DEPARTMENT OF THE NAVY
THE SURGEON GENERAL, DEPARTMENT OF THE AIR FORCE

SUBJECT: Recommendation for a Research Study on Pneumococcal Vaccine

- 1. To assess whether a single dose of the 23 valent pneumococcal polysaccharide vaccine should be recommended for routine use in military recruits, data are needed on the likely impact of the vaccine. Factors which make the pneumococcal vaccine likely to be useful in the recruit/training setting include:
  - a. Documented outbreaks of pneumococcal disease in recruits (i.e. Camp Pendleton, Rangers).
  - b. Data showing substantial pneumonia morbidity based on medical record review, with morbidity particularly increased during the initial recruit period. While definitive diagnosis of most pneumonias is difficult, many of these cases may be of pneumococcal etiology.
  - c. A controlled vaccine trial of the pneumococcal vaccine is a way to estimate what proportion of pneumonia is preventable in recruits by use of pneumococcal vaccine, as well as the expected impact on pneumonia, sick days, and costs.
  - d. Increasing antimicrobial resistance in pneumococcal isolates worldwide, including the United States, is substantially increasing the risk and cost of treating pneumococcal disease.
- 2. Therefore, the Infectious Disease Subcommittee, with the approval from the full Board of the AFEB, recommends that:

A CONTROLLED STUDY OF THE IMPACT OF PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN RECRUITS BE UNDERTAKEN. CAREFUL ATTENTION SHOULD BE GIVEN IN DESIGNING THE STUDY TO ADDRESS POTENTIAL EFFECTS OF SEASONALITY, COINCIDENT OUTBREAKS OF OTHER RESPIRATORY DISEASES, IMPACT OF OTHER VACCINES SUCH AS ADENOVIRUS AND INFLUENZA, AND THE POSSIBLE HERD EFFECT OF VACCINATION.

AFEB (15-1a) 98-3 09 January 1998 SUBJECT: Recommendation for a Research Study on Pneumococcal Vaccine

3. This recommendation was approved by the full Board on 12 December 1997.

FOR THE ARMED FORCES EPIDEMIOLOGICAL BOARD:

GERALD F. FLETCHER, M.D.

AFEB President

VICKY L. FOGELMAN Colonel, BSC, USAF

AFEB Executive Secretary

## Copies Furnished:

The Surgeon General, USA

The Surgeon General, USAF

The Surgeon General, USN

Board Members

DASG-ZH

AFMOA/CC

Ch, Prev Med Div, OTSG-DA

Ch, Prev Med Div, OTSG-DAF

Dir. Occup Hlth & Prev Med Div, BUMED-DN

CDR, WRAIR

CDR, USAMEDCOM, ATTN: MCHO-CL-W

CDR, USACHPPM, ATTN: MCHB-DP

CDR, U.S. MRMC-ZA

Navy Env. Health Center

Dir, Med Resources, Plans & Policy Div. (N931)

Head, Epi Dept., NEPMU 5

CDR Barbara A. Braden, USCG

COL Andrew S. Warde, ByetMed Msc MRCVS

LCOL Frank Souter, CFMS